Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-4 R alpha

IL-4 R alpha

Brief Information

Name:Interleukin-4 receptor subunit alpha
Target Synonym:Interleukin 4 Receptor,IL-4 Receptor Subunit Alpha,Interleukin 13 Receptor,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Variant 1,IL-4R Subunit Alpha,CD124 Antigen,Interleukin-4 Receptor alpha Subunit,IL4Rα,IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4-binding protein,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,IL4R
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILR-H5253-ELISA
 IL-4 R alpha ELISA

Immobilized Human IL-4, premium grade (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well)can bind Human IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) with a linear range of 1-20 ng/mL (QC tested).

ILR-H82F4-MALS-HPLC
IL-4 R alpha MALS images

The purity of Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) is more than 90% and the molecular weight of this protein is around 120-147 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

IL4R,CD124,IL4RA

Background

IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132).Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a  type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-­biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL­13Ra1 to form the type II receptor which is responsive to both IL­4 and IL­13. Interleukin-4 receptor has been shown to interact with SHC1.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Dupilumab REGN-668; SAR-231893 Approved Sanofi, Regeneron Pharmaceuticals Inc Dupixent, 达必妥 United States Dermatitis, Atopic Regeneron Pharmaceuticals Inc 2017-03-28 Keloid; Prurigo; Colitis, Ulcerative; Neurodermatitis; Sinusitis; Urticaria; Pemphigoid, Bullous; Duodenitis; Peanut Hypersensitivity; Pulmonary Disease, Chronic Obstructive; Asthma; Paranasal Sinus Diseases; Hypersensitivity, Immediate; Scleroderma, Localized; Keratoconjunctivitis; Asthma, Aspirin-Induced; Dermatitis, Atopic; Eczema; Hypersensitivity; Angioedema; Milk Hypersensitivity; Eosinophilic gastroenteritis (EG); Pruritus; Gastrointestinal Diseases; Alopecia Areata; Nasal Polyps; Chronic Urticaria; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Respiration Disorders; Aspergillosis, Allergic Bronchopulmonary; Dermatitis; Skin Diseases, Eczematous; Skin Diseases; Genetic Diseases, Inborn; Eosinophilic Esophagitis; Rhinitis, Allergic; Sleep Apnea Syndromes; Prostatic Neoplasms; Conjunctivitis, Allergic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Manfidokimab AK-120 (Akeso ) Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Asthma; Dermatitis, Atopic Details
HY-1770 HY1770; HT-17; HT17; HY-1770 Phase 1 Clinical Suzhou Pharmavan Co Ltd Dermatitis, Atopic; Plaque psoriasis Details
NM26-2198 NM-26-2198 Phase 1 Clinical Kaken Pharmaceutical Co Ltd, Numab Therapeutics Ag Inflammation; Dermatitis, Atopic Details
Comekibart MG-010; MG-K-10; BC-005; MG-K10 Phase 3 Clinical Shanghai Mabgeek Biotechnology Co Ltd, Dragonboat Biopharmaceutical Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic Details
Rademikibart CBP-201 Phase 2 Clinical Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps; Nose Diseases; Iron deficiency; Sinusitis; Status Asthmaticus; Asthma; Dermatitis, Atopic Details
Elarekibep PRS-060/AZD1402; PRS-060; AZD-1402 Phase 1 Clinical University Of Melbourne, Pieris Pharmaceuticals Asthma Details
Bizaxofusp PRX-321; MDNA-55; IL4-PE; NBI-3001 Phase 2 Clinical Neurocrine Biosciences Inc, National Institute of Health, Islamabad Kidney Neoplasms; HIV Infections; Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Glioma; Sarcoma, Kaposi Details
BA-2101 BA-2101; BA2101 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Nasal Polyps; Chronic Urticaria; Asthma; Sinusitis; Prurigo; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details
SHR-1819 SHR-1819 Phase 2 Clinical Atridia Pty Ltd Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic Details
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) 611; 611 Q2W; 611 Q4W; 611-3SBio; SSGJ-611 Phase 3 Clinical Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd Nasal Polyps; Polyps; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details
LQ-036 LQ-036 Phase 1 Clinical Shanghai Novamab Biopharmaceuticals Co Ltd Asthma; Pulmonary Disease, Chronic Obstructive Details
Sorafenib Tosylate/Comekibart MG-D-1609 Phase 2 Clinical Metagone Biotech Inc Solid tumours Details
RC-1416 Phase 1 Clinical Nanjing Rongjiekang Biotechnology Co Ltd Asthma Details
QX-005N QX-005N Phase 2 Clinical Qyuns Therapeutics Co Ltd Chronic Urticaria; Nasal Polyps; Prurigo; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic Details
siLR4A siLR4A Phase 3 Clinical National Skin Centre, Singapore Keloid; Wounds and Injuries Details
BSI-045A BSI-045A Clinical Biosion Inc Dermatitis, Atopic Details
TQH2722 TQH-2722; TQH2722 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Nasal Polyps; Sinusitis; Dermatitis, Atopic Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message